Cancer News

FDA Approves Vyxeos for Adults with Poor Prognosis AML (08/07/2017)

The U.S. Food and Drug Administration granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. This is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC. Approval …

Continue reading "FDA Approves Vyxeos for Adults with Poor Prognosis AML"

Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome (02/21/2017)

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation therapy that is likely to produce the best results, according to new research by scientists at Dana-Farber Cancer …

Continue reading "Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome"

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes (08/31/2016)

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology. Myelodysplastic syndromes (MDS) refer to a group of diseases in which … Continue reading "Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes"